All In Biotech

Drug Trial Radar · NCT07680166

An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Oct 31, 2029

Study completion Oct 31, 2029

Sponsor

Lead sponsor
Xentria, Inc.Industry
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of XTMAB-16 in patients with pulmonary sarcoidosis

Conditions

  • Pulmonary Sarcoidosis

Interventions

  • XTMAB-16Drug

    Infusion

  • PlaceboDrug

    Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 24Time frame: Baseline to Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.